Genomic Profiling of Chronic Myelogenous Leukemia: Basic and Clinical Approach.
10.15430/JCP.2017.22.2.74
- Author:
Aliasghar KERAMATINIA
1
;
Alireza AHADI
;
Mohammad Esmaeil AKBARI
;
Maryam MOHSENY
;
Alireza Mosavi JARAHI
;
Narjes MEHRVAR
;
Neda MANSOURI
;
S A Mortazavi TABATABAEI
;
Abolfazl MOVAFAGH
Author Information
1. Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. movafagh.a@sbmu.ac.ir
- Publication Type:Review
- Keywords:
Chronic myeloid leukemia;
Profile;
Methods;
BCR-ABL1
- MeSH:
Chromosomes, Human;
Cytogenetics;
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*;
Methods;
Philadelphia Chromosome;
Phosphotransferases;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
Protein-Tyrosine Kinases;
Stem Cells;
Translocation, Genetic
- From:Journal of Cancer Prevention
2017;22(2):74-81
- CountryRepublic of Korea
- Language:English
-
Abstract:
Chronic myeloid leukemia (CML) is a hematological stem cell cancer driven by BCR-ABL1 fusion protein. We review the previous and recent evidence on the significance of CML in diagnostic and clinic management. The technical monitoring of BCR-ABL1 with quantitative real time-PCR has been used in assessing patient outcome. The cytogenetic mark of CML is Philadelphia chromosome, that is formed by reciprocal chromosomal translocations between human chromosome 9 and 22, t(9:22) (q³⁴:q¹¹). It makes a BCR-ABL1 fusion protein with an anomaly tyrosine kinase activity that promotes the characteristic proliferation of progenitor cells in CML and acute lymphoblastic lymphoma. The targeting of BCR-ABL1 fusion kinase is the first novel paradigm of molecularly targeted curing.
